All News
Jonassen et al. AP1189, an oral melanocortin agonist in combination with MTX in early RA. Evidence of efficacy, no safety concerns. Looks promising! @RheumNow #ACR22 Abstr#1985 https://t.co/aK7BPwr5Ku https://t.co/9553KT2Pao
Richard Conway RichardPAConway ( View Tweet)
van Ouwerkerk et al. Glucocorticoid bridging in new RA associated higher risk of starting bDMARD (aHR 1.68) but not glucocorticoids (aHR 1) later in disease. Why? Maybe it shows what can be achieved? @RheumNow #ACR22 Abstr#1994 https://t.co/5GsXGMOZAm https://t.co/122CuSAqVw
Richard Conway RichardPAConway ( View Tweet)
Damart et al. Treatment strategies in CPP arthritis. Colchicine(1st line=73/86), MTX (second line=22/36), anakinra (n=27) and TCZ (n=25) most used. Drug survival MTX vs colchicine HR 0.64, TCZ vs anakinra HR 0.55 @RheumNow #ACR22 Abstr#1795 https://t.co/4PtxQNmTqV https://t.co/BKM4Ff9Gkk
Richard Conway RichardPAConway ( View Tweet)
#ACR22 Abs 1863 Aromatase Inhibitor induced musculoskeletal inflammation observed independent of oophorectomy in novel mouse model, may not be E2 related as previously thought. @RheumNow https://t.co/XhUaGQX88p
Dr. Rachel Tate uptoTate ( View Tweet)
Are we asking women with IPAF about family planning?
Abstract #0944 #ACR22 @RheumNow
🫁 31 women
🤰83% had RF for adverse pregnancy outcomes
👼1/3 women had family plan. or birth control talks with pulm. docs
✋>50% women who saw a rheumatologist discussed these topics
Catherine Sims, MD DrCassySims ( View Tweet)
Rheum/ILD combined clinics may help dx ILD assoc'd CTD that is underdiagnosed currently. Pic below is very informative! Abs 1874 #ACR22 @RheumNow https://t.co/rr0QEfqicv https://t.co/V6eTyz1BuV
Dr. Rachel Tate uptoTate ( View Tweet)
Tofa may be option for pts w/ refractory skin predominant dermatomyositis. Abs 1887 #ACR22 @RheumNow https://t.co/heJ1kZeuPT https://t.co/CqK0dL7DQK
Dr. Rachel Tate uptoTate ( View Tweet)
#abst2109 #ACR22 @RheumNow GO-VIBRANT bio-naïve pts w/active PsA Rx w/IV GLM tend respond slower in all domains if ⬆️ age, HAQ-DI score, and spinal pain; smoking gives w/lower odds of HAQ-DI ≤0.5 at W52. minimal SJC& ⬇️enthesitis achieved significantly faster than TJC, HAQ-DI https://t.co/qqmjEAq3Cd
Olga Petryna DrPetryna ( View Tweet)
#ACR22 Abstr#L08 Is Evusheld effective in the first 6 mths of therapy in #COVID Omicron era? A cohort study of 157 RMD patients who were fully vaccinated reported 24 (15%) breakthrough infection; only 2 (1%) required hospitalisation. COVID occurred ~3mths post-therapy @RheumNow https://t.co/VJogB2otbn
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Possible new biomarker in early RA? RA patients with high level of measurable fibrogenesis (PRO-C3 serum levels) less likely to respond to TCZ, as compared to patients with low level of fibrogenesis. Abs 1986 #ACR22 @RheumNow https://t.co/xnyoV2xbWq https://t.co/Vka8UZsrar
Dr. Rachel Tate uptoTate ( View Tweet)
@RheumNow #ACR22 https://t.co/dO7xDTApqP
Olga Petryna DrPetryna ( View Tweet)
Immunosuppressants (eg. MTX, RTX, MMF) can reduce immunogenicity to vaccines. VACIMRA study showing no difference in disease activity (beyond 1 month) and damage when MTX initiation was delayed by 1 month for the PCV13 pneumococcal vaccine.
@RheumNow ABST1960 #ACR22 https://t.co/SKQ2qx3lJG
Julian Segan JulianSegan ( View Tweet)
💤Our PsA patients are not sleeping well 💤
Abstract #0387 #ACR22 @RheumNow
😴 247 patients, sleep quality measured via PSQI
🛌 63% had poor sleep quality
💤 Worse sleep associated with female sex, higher disease activity, fatigue, anxiety/depression https://t.co/Wy20qx2Ah4
Catherine Sims, MD DrCassySims ( View Tweet)
To taper or not to taper?
In this prospective study by Dr. Cho, #SLE patients in complete remission had a longer time to flare upon drug tapering vs. those in LLDAS or clinical remission states.
#ACR22 @RheumNow ABST#0996 #ACRBEst @rheumarhyme https://t.co/bSGlkc7Tvk
sheila RHEUMarampa ( View Tweet)
#ACR22 Abs 1752 finds rates of incident cancer did not differ between patients treated with anti-TNF and other bDMARDs or tsDMARDs. @RheumNow https://t.co/ycnQzrmAjw https://t.co/CSgDq2Gazg
Dr. Rachel Tate uptoTate ( View Tweet)
Abs 1757 at #ACR22 finds women w/ gout have a higher risk of all-cause mortality, which is primarily driven by higher risk of CVD deaths. @RheumNow https://t.co/kPDL2VYRCN https://t.co/9qARr7T4fI
Dr. Rachel Tate uptoTate ( View Tweet)
Abs L04 reviews novel humanized murine model of PsA disease phenotypes mediated by CD8 T Cells. Perhaps this is a step forward in personalized medicine. #ACR22 @RheumNow https://t.co/fPoElqFLI7 https://t.co/4pxBKoPnym
Dr. Rachel Tate uptoTate ( View Tweet)
Prof Petri presents mortality data of their #lupus cohort
🔅55 yrs - ave age of death from all causes
Top 4 common causes of death:
🔅SLE
🔅CVD
🔅Cancer
🔅Infection
African-americans had ⬆️proportions of death from infections & renal causes
#ACR22 @RheumNow #ABST2068 https://t.co/B5cAfZiRJp
sheila RHEUMarampa ( View Tweet)
Is sustained B cell depletion assoc w/⬇️dse flares in #lupus nephritis?
In this study by Dr D Zisa, pts treated w/ BCA & had sustained Bcell depletion = ⬇️dse flares
👉Rapid repletion to BCC>100c/uL was assocd w/ 15.2x risk for flares
#ACR22 @RheumNow ABST2065 https://t.co/ivSjm98YvZ
sheila RHEUMarampa ( View Tweet)
Is there a difference between IL-17i and TNFi in preventing radiographic progression in radiographic axSpA?
Head to head study secukinumab vs. adalimumab biosimilar shows no sig difference with low radiographic progression.
#ACRBest Abs#L15 @RheumNow #ACR22 https://t.co/UiHMtakaPz
Robert B Chao, MD doctorRBC ( View Tweet)